Abstract 25P
Background
With the advent of novel antibody-drug conjugate (ADC), an emerging subgroup of human epidermal growth factor receptor 2 (HER2)-low breast cancer has been recognized which may take advantage from the anti-tumor activity. We took advantage of Taiwan Cancer Registry (TCR) to evaluate the clinical presentations and prognostication for HER2-low breast cancer.
Methods
HER2-low breast cancers were defined operationally with HER2 immunohistochemistry (IHC) 1+ or 2+ with a negative fluorescence in situ hybridization (FISH) while HER2-zero defined with an IHC score 0. Breast cancer index cases (n=189465) from TCR between 2007 and 2017 were reduced to 133546 sides of breast cancer per subject. Clinical features such as IHC test, stage, grade and outcomes such as relapse-free and overall survival were compared between HER2-low and HER2-zero.
Results
The safety analysis group comprised 37195 HER2-negative breast cancers, including 14288 IHC 1+, 10486 FISH-negative, 8907 IHC 0 and 3323 IHC 2+/FISH-undetermined cases. Among HER2-negative breast cancers, the proportion of HER2-low and HER2-zero was 68.9% and 31.1%, respectively, after excluding HER2 ambiguity. Overall survival was 95.7% versus 95.9% for HER2-low and HER2-zero breast cancers, which was 94.1% and 94.7% for relapse-free survival. The distributions of pathological stages from 0 to IV were 6.7%, 41.5%, 38.5%, 13.1% and 0.3% for HER2-low and were 8.5%, 42.8%, 37.5%, 11% and 0.4% for HER2-zero breast cancers. Regarding estrogen receptor (ER) and progesterone receptor (PR) status, 87.6% and 80.9% of the HER2-low cases were ER+ and PR+ while 81.9% and 74.8% of the HER2-zero patients were ER+ and PR+. High or poorly differentiated grade was reported from 23.4% of HER2-low and 25.5% of HER2-zero breast cancers. The diagnosed age was 54 versus 54.3 between HER2-low and HER2-zero breast cancers (P=0.02).
Conclusions
HER2-low status is not a prognostic marker for Taiwanese breast cancers while a slightly younger age of disease onset, less than half diagnosed with stage 0 and I, more ER and PR positivity and fewer grade III disease were observed for HER2-low phenotype compared with HER2-zero counterpart. These trivial differences distinguished HER2-low from HER2-zero spectrum among Taiwanese HER2-negative breast cancers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
LMT.
Funding
Melissa Lee Cancer Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract